Abera Bioscience AB (NGM: ABERA)

Abera Bioscience AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	2.63	3.3	15.43	11.95	0.9	2.65
Cash & Short-Term Investments	2.63	3.3	15.43	11.95	0.9	2.65
Cash Growth	-49.44%	-78.64%	29.12%	1224.40%	-65.97%	434.09%
Other Receivables	0.77	0.77	0.77	0.3	0.18	0.35
Receivables	0.77	0.77	0.77	0.3	0.18	0.35
Prepaid Expenses	5.41	3.38	1.49	0.19	-	-
Other Current Assets	-	0	-0	-	-	-
Total Current Assets	8.81	7.44	17.69	12.44	1.08	3
Long-Term Investments	-	0.03	-	-	-	-
Long-Term Deferred Charges	1.89	1.89	1.89	1.89	1.89	1.89
Other Long-Term Assets	-	-	-	17.05	-	-
Total Assets	11.1	9.35	19.57	31.37	2.97	4.89
Accounts Payable	1.11	2.2	1.67	0.99	0.13	0.09
Accrued Expenses	0.86	1.23	0.97	1.17	1.36	0.73
Other Current Liabilities	0.33	0.27	0.16	0.07	1.05	-
Total Current Liabilities	2.3	3.69	2.8	2.22	2.54	0.82
Other Long-Term Liabilities	-0	-	-0	-0	-	-
Total Liabilities	2.3	3.69	2.8	2.22	2.54	0.82
Common Stock	1.23	1.16	1.03	0.84	0.56	0.09
Additional Paid-In Capital	68.96	64.86	59.39	52.49	14.97	14.97
Retained Earnings	-61.38	-60.83	-44.11	-24.73	-15.56	-11.92
Comprensive Income & Other	-	0.47	0.47	0.56	0.47	0.93
Shareholders' Equity	8.8	5.66	16.78	29.15	0.43	4.07
Total Liabilities & Equity	11.1	9.35	19.57	31.37	2.97	4.89
Net Cash (Debt)	2.63	3.3	15.43	11.95	0.9	2.65
Net Cash Growth	-49.44%	-78.64%	29.12%	1224.40%	-65.97%	434.09%
Net Cash Per Share	0.19	0.25	1.32	1.17	0.13	1.14
Filing Date Shares Outstanding	14.46	14.46	12.91	11.57	10.46	2.33
Total Common Shares Outstanding	14.46	14.46	12.91	11.57	6.97	2.33
Working Capital	6.51	3.75	14.89	10.21	-1.46	2.18
Book Value Per Share	0.61	0.39	1.30	2.52	0.06	1.75
Tangible Book Value	8.8	5.66	16.78	29.15	0.43	4.07
Tangible Book Value Per Share	0.61	0.39	1.30	2.52	0.06	1.75

Source: S&P Capital IQ. Standard template. Financial Sources.